mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
==== Adults ==== For the general population of healthy adults, Health Canada advises a daily intake of no more than 400 mg. This limit was found to be safe by a 2017 systematic review on caffeine toxicology.
=== 18th century === By the 18th century, the medicinal properties of opium and laudanum were well known, and the term "laudanum" came to refer to any combination of opium and alcohol. In the 18th century several physicians published works about it, including John Jones, who wrote The Mysteries of Opium Revealed (1700), which was described by one commentator as "extraordinary and perfectly unintelligible". The Scottish physician John Brown, creator of the Brunonian system of medicine, recommended opium for what he termed asthenic conditions, but his system was discredited by the time of his death. The most influential work was by George Young, who published a comprehensive medical text entitled Treatise on Opium (1753). Young, an Edinburgh surgeon and physician, wrote this to counter an essay on opium by his contemporary Charles Alston, professor of botany and materia medica at Edinburgh who had recommended the use of opium for a wide variety of conditions. Young countered this by emphasising the risks '...that I may prevent such mischief as I can, I here give it as my sincere opinion... that opium is a poison by which great numbers are daily destroyed.' Young gives a comprehensive account of the indications for the drug including its complications. He is critical about writers whose knowledge of the drug is based on chemical or animal experiments rather than clinical practice. The treatise is a detailed, balanced and valuable guide to prevailing knowledge and practice.
== History == The natural immunity of snakes to their own venom was observed at least as early as 1767, by Felice Fontana in his work Ricerche Fisiche sopra il Veleno della Vipera (Physical Research on the Venom of the Viper). Scottish surgeon and naturalist Patrick Russell also noted in the late 18th century that snakes were not affected by their own venom. Surgeon-Major Edward Nicholson wrote in the November 1870 Madras Medical Journal that he had witnessed a Burmese snake-catcher inoculating himself with cobra venom. However, the snake-catcher was unsure whether this was actually effective and therefore continued to treat his snakes with care. The notion of inducing immunity to venom was tested in laboratories around the world. In 1887, Dr. Henry Sewall in Michigan achieved artificial immunity to rattlesnake (Sistrurus catenatus catenatus) venom in pigeons by repeated inoculation of venom, starting with a sub-lethal dose and progressively increasing in strength until resistance developed to doses seven times the lethal dose in untreated pigeons. From 1889 to 1892, Maurice Kaufmann at the École nationale vétérinaire d'Alfort studied the effect of successive inoculations of weak doses of Vipera aspis venom on animals. Although proving that a greater resistance to low doses was possible, Kauffman was unable to achieve complete immunity against the venom at the lethal dose. The breakthrough came with the use of serum from an immunized animal to counter the effects in an unexposed animal.
Andrés de Santa Cruz, who would have had apparent contradictions in his geopolitical projects, due to a highland nationalism, in which he wanted both the reunification of Upper and Lower Peru (in a similar way to the Inca Empire or the Viceroyalty of Peru) as well as to consider dividing Peru into 2 states, one from the north and the other from the south, for the benefit of Bolivia's interests (in addition to recovering the territory of Arica for the benefit of Bolivia), which he envisioned as the "Macedonia of America" and which should have a leadership in the continent, to the detriment of the historical preponderance of Lima and Cuzco as poles of power."When he felt strong, his dreams of power were those of those legendary Incas who descended from the mountains to bring peace, order, and progress to the coast. Then he opened himself to the ideal of 'pan-Peru', of Greater Peru. Bolivia would be the "Macedonia of America". If they beat and humiliated him and cornered him on the plateau, he wanted, not so much for revenge as for security reasons, next to Bolivia, a divided or impotent Peru. His maximum program was a strong Greater Peru and extensive, that is, the Confederation, with him as head. His minimum program was to govern Bolivia, but, at his side, the bifurcation of Peru into two states and the possible fall of the South State under Bolivia's sphere of influence Such is the explanation of his political behavior until 1839.
Sources: en.wikipedia.org
Since the tight control of enzyme activity is essential for homeostasis, any malfunction (mutation, overproduction, underproduction or deletion) of a single critical enzyme can lead to a genetic disease. The malfunction of just one type of enzyme out of the thousands of types present in the human body can be fatal. An example of a fatal genetic disease due to enzyme insufficiency is Tay–Sachs disease, in which patients lack the enzyme hexosaminidase. One example of enzyme deficiency is the most common type of phenylketonuria. Many different single amino acid mutations in the enzyme phenylalanine hydroxylase, which catalyzes the first step in the degradation of phenylalanine, result in build-up of phenylalanine and related products. Some mutations are in the active site, directly disrupting binding and catalysis, but many are far from the active site and reduce activity by destabilising the protein structure, or affecting correct oligomerisation. This can lead to intellectual disability if the disease is untreated. Another example is pseudocholinesterase deficiency, in which the body's ability to break down choline ester drugs is impaired. Oral administration of enzymes can be used to treat some functional enzyme deficiencies, such as pancreatic insufficiency and lactose intolerance. Another way enzyme malfunctions can cause disease comes from germline mutations in genes coding for DNA repair enzymes. Defects in these enzymes cause cancer because cells are less able to repair mutations in their genomes.
==== Singapore ==== Oxycodone is listed as a Class A drug in the Misuse of Drugs Act of Singapore, which means offences concerning the drug attract the most severe level of punishment. A conviction for unauthorized manufacture of the drug attracts a minimum sentence of 10 years of imprisonment and corporal punishment of 5 strokes of the cane, and a maximum sentence of life imprisonment or 30 years of imprisonment and 15 strokes of the cane. The minimum and maximum penalties for unauthorized trafficking in the drug are respectively 5 years of imprisonment and 5 strokes of the cane, and 20 years of imprisonment and 15 strokes of the cane.
=== Liver effects === The concomitant use of caspofungin and ciclosporin in healthy volunteers led to a more frequent increase of liver enzymes (ALT=SGPT and AST=SGOT) than noted with cyclosporine alone.
==== Nematodes ==== For example, in the roundworm Caenorhabditis elegans, which feeds on bacteria, serotonin is released as a signal in response to positive events, such as finding a new source of food or in male animals finding a female with which to mate. When a well-fed worm feels bacteria on its cuticle, dopamine is released, which slows it down; if it is starved, serotonin also is released, which slows the animal down further. This mechanism increases the amount of time animals spend in the presence of food. The released serotonin activates the muscles used for feeding, while octopamine suppresses them. Serotonin diffuses to serotonin-sensitive neurons, which control the animal's perception of nutrient availability.
The production of the hormone melatonin, a sleep regulator, is inhibited by light and permitted by darkness as registered by photosensitive ganglion cells in the retina. To some degree, the reverse is true for serotonin, which has been linked to mood disorders. Hence, for the purpose of manipulating melatonin levels or timing, light boxes providing very specific types of artificial illumination to the retina of the eye are effective. Light therapy uses either a light box which emits up to 10,000 lux of light at a specified distance, much brighter than a customary lamp, or a lower intensity of specific wavelengths of light from the blue (460 nm) to the green (525 nm) areas of the visible spectrum. A 1995 study showed that green light therapy at doses of 350 lux produces melatonin suppression and phase shifts equivalent to 10,000 lux white light therapy, but another study published in May 2010 suggests that the blue light often used for SAD treatment should perhaps be replaced by green or white illumination, because of a possible involvement of the cones in melatonin suppression.
Sources: en.wikipedia.org
Eukaryotic translation initiation factor 4E, also known as eIF4E, is a protein in humans encoded by the EIF4E gene. eIF4E plays a central role in translation initiation and is involved in regulating protein synthesis. Its mRNA cap-binding activity influences a range of biological processes and disease states, making it an important target for therapeutic development, particularly in disorders characterized by aberrant protein production.
A small number of cities, towns, and intentional communities around the world are exclusively vegetarian where no meat is sold or consumed due to religious and cultural influences. In all-vegetarian locations, meat and sometimes other animal products are sometimes officially outlawed. In other exclusively vegetarian cities, meat is not sold or served due to cultural influences but is not officially outlawed. Some religious centers in India have banned all meat sales within municipal boundaries. For example, in 1956, Rishikesh banned the sale of meat, fish, and eggs. Locations where residents are vegetarian and only vegetarian food is consumed within city limits include:
=== Identification of the active compound === While working at the Bureau of Dairy Industry, U.S. Department of Agriculture, Mary Shaw Shorb was assigned work on the bacterial strain Lactobacillus lactis Dorner (LLD), which was used to make yogurt and other cultured dairy products. The culture medium for LLD required liver extract. Shorb knew that the same liver extract was used to treat pernicious anemia (her father-in-law had died from the disease), and concluded that LLD could be developed as an assay method to identify the active compound. While at the University of Maryland, she received a small grant from Merck, and in collaboration with Karl Folkers from that company, developed the LLD assay. This identified "LLD factor" as essential for the bacteria's growth. Shorb, Folker and Alexander R. Todd, at the University of Cambridge, used the LLD assay to extract the anti-pernicious anemia factor from liver extracts, purify it, and name it vitamin B12. In 1955, Todd helped elucidate the structure of the vitamin. The complete chemical structure of the molecule was determined by Dorothy Hodgkin based on crystallographic data and published in 1955 and 1956, for which, and for other crystallographic analyses, she was awarded the Nobel Prize in Chemistry in 1964. Hodgkin went on to decipher the structure of insulin. George Whipple, George Minot and William Murphy were awarded the Nobel Prize in 1934 for their work on the vitamin. Three other Nobel laureates, Alexander R.
=== Myocardium / cardiomyopathy === (I40) Acute myocarditis (I41) Myocarditis in diseases classified elsewhere (I42) Cardiomyopathy (I42.0) Dilated cardiomyopathy (I42.1) Obstructive hypertrophy cardiomyopathy (I42.2) Other hypertrophic cardiomyopathy (I42.3) Endomyocardial (eosinophilic) disease Eosinophilic myocarditis Endomyocardial (tropical) fibrosis Löffler's endocarditis (I42.4) Endocardial fibroelastosis (I42.5) Other restrictive cardiomyopathy (I42.6) Alcoholic cardiomyopathy (I42.8) Other cardiomyopathies Arrhythmogenic right ventricular dysplasia (I43) Cardiomyopathy in diseases classified elsewhere
During the British Raj, there were multiple American missionaries sent to India, including the well known Scudder family, Ralph T. Templin, James Mills Thoburn, Mary W. Bacheler, James Mudge, J. Waskom Pickett, Edward Winter Clark, Miles Bronson, Samuel H. Kellogg, John Nelson Hyde, Nancie Monelle, Lucy Whitehead McGill Waterbury Peabody, Crawford R. Thoburn, Elwood Morris Wherry, Murray Thurston Titus, Titanic victim Annie Funk, Frederick Bohn Fisher, British Raj born & World War II victim Robert M. Hanson, British Raj born Victor Clough Rambo, Hervey De Witt Griswold, British Raj born Robert Ernest Hume, British Raj born John Lawrence Goheen, British Raj born John William Theodore Youngs, Beatrice Marian Smyth, Anna Sarah Kugler, William H. Wiser, Julia Jacobs Harpster, Charlotte C. Wyckoff, Isabella Thoburn, and American expatriate turned Indian freedom fighter Satyananda Stokes. The Scudder family was renowned for its multigenerational missionary work in India, particularly in the fields of medicine, education, and Christian evangelism. Led by Dr. John Scudder Sr., who arrived in South Asia in 1819 as one of the first medical missionaries sent by the American Board of Commissioners for Foreign Missions (ABCFM), the family established hospitals and dispensaries across the region. Dr. John Scudder Jr. continued this legacy, founding the Arcot Mission in Vellore, Tamil Nadu, and later the Ceylon Mission in Sri Lanka. Notably, Dr. Ida Scudder, granddaughter of Dr.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.